News

Biosciences Research Institute first of its kind

Indiana Governor Mike Pence joined industry and research university executives to unveil the Indiana Biosciences Research Institute.  The industry-led collaborative life sciences research institute is a statewide public-private partnership advanced by BioCrossroads and the first of its kind.

The Indiana Biosciences Research Institute is the result of leadership from industry executives from Eli Lilly, Dow AgroSciences, Roche Diagnostics, Cook Medical, Indiana University Health and Biomet with support and development by BioCrossroads.  Indiana’s research institutions participating in the development process are Indiana University, Purdue University, and the University of Notre Dame.

Jon Serbousek, president of Biomet Biologics says the institute is a cross-industry, statewide partnership focused on commercially translatable innovation on the cutting edge of basic and clinical science to help the state’s life sciences industry move to the next level.

The estimated $360-million Indiana Biosciences Research Institute is a non-profit entity that is anticipated to be supported largely by corporate and philanthropic funding with oversight from a largely donor-based board of directors representing the life sciences industry, the state of Indiana, academia and nonprofit donors. The State of Indiana has appropriated $25 million for the biennium for start-up costs. An additional $25 million in start-up funding is being sought from industry and philanthropic sources, which will be used in part to recruit a nationally recognized CEO and research fellows.

More information can be found at www.indianabiosciences.org.